RxDoctor Payments Data

Anna Gaddy, MD

Nephrology · Milwaukee, WINPI 1619326980

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,777 of the $28,173 with a category attached, or 87.9%. 8 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 43.0% of the total. Among nephrology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,173in general payments, 2019–2025

Across 34 payments — averaging $828.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
  • Travere Therapeutics, Inc.$9K
  • Otsuka America Pharmaceutical, Inc.$4K
  • Calliditas Therapeutics US Inc.$2K
  • Mallinckrodt Hospital Products Inc.$229
  • Novartis$165
  • plus $198 from 2 others

What the payments were for

  • Consulting fees$24,77788%
  • Travel & lodging$1,5766%
  • Food & beverage$1,8206%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,173 in reported general payments places this provider in the 95th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$45,528
Medicare patients
155
Services billed
418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$161,194
LokelmaSodium Zirconium Cyclosilicate19$15,103
Verapamil SrVerapamil Hcl23$3,900
Valsartan23$723
Verapamil ErVerapamil Hcl17$642
Losartan Potassium69$613
Amlodipine Besylate62$403
Spironolactone47$390
Chlorthalidone17$336
Carvedilol28$283
Metolazone13$272
Furosemide46$224
Nifedipine ErNifedipine20$212
Lisinopril58$194
Tamsulosin Hcl23$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$125$15,10319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →